An important 2018 for the legal department at Summit-based biotechnology company Celgene Corp. wasn’t capped, really, until 2019: Early in the year, when the acquisition by Bristol-Myers Squibb Co. was announced, and in mid-April, when the $74 billion transaction garnered an approving vote by shareholders.
Celgene and Bristol-Myers announced the deal on Jan. 3: “Combining with Bristol-Myers Squibb, we are delivering immediate and substantial value to Celgene shareholders and providing them meaningful participation in the long-term growth opportunities created by the combined company,” Celgene chief executive Mark Alles said in a statement at the time.
